

Minutes of Pre-bid meeting held on 01/07/2013 at 14:00 hr at RITES office for Supply of ARV Drugs (ANTI RETRO-VIRAL DRUGS) (ADULT FIRST LINE) against: IFB No. RITES/MSM/NACP/01/2013

1. The following were present:-

I) From RITES

S/Shri

A Sharma, GGM/MSM– In Chair

P Mirani, GM/MSM

R K Sharma, Sr.DGM/MSM

M K Das, Manager/MSM

Anil Gupta, Pharmaceutical Expert/MSM

II) From NACO

Dr. Reshu Agarwal, PO/NACO

III) Firms which attended the pre bid conference are as follows:

S. No.	Name of representative S/Shri	Name of Firm
1.	Ravi Mehta	M/s Ranbaxy Laboratories Ltd., Gurgaon
	Sandeep Sarkar	
	Taher Karampurwala	
	Sumit Misra	
	J Ganesh	
2.	S. Ranjit Singh	M/s Hetero Drugs Ltd., Hyderabad
3.	Raja Mahesh	M/s Aurobindo Pharma Ltd., Hyderabad
	Arun Sharma	M/s Pharmimax India
4.	Vijay Chauhan	M/s Emcure Pharmaceuticals Ltd., Pune
5.	A K Rastogi	M/s Cipla Ltd., Mumbai

2. Initiating the discussion, chairperson welcomed the participants. It was explained that purpose of Pre-bid meet is to educate the bidders regarding various important provisions of the bidding documents and also to clarify any queries that the bidders may have in the subject bidding documents.

3. The issues raised during the pre bid meeting and clarifications are as under-

S. No.	Query Raised	Clarification
	Section II: Bid Data Sheet	
1.	M/s Aurobindo Pharma and M/s Hetero have advised that custom authorities will not entertain custom duty exemption certificate (CDEC) issued from NACO as GFATM has still not been included in the list of international donors. These bidders want a confirmation from NACO that in case custom authorities do not accept CDEC issued from NACO and they are forced to pay Custom Duty then the same would be reimbursed by NACO. (Refer ITB 16.2 (a) &	Custom Duty Exemption Certificate (CDEC) will be issued, if applicable. In case, the duty is paid, the same will be reimbursed by NACO (DAC) upon production of original documentary evidence. Please also refer Amendment No. 1.

S. No.	Query Raised	Clarification
	<i>16.2 (b)(i) at page 45-46)</i>	
	Section V. Special Conditions of Contract:	
	All the participants have requested to permit them to supply each Lot in two/three installments as quantities are very large.	Supply of each Lot in two installments is permitted. Please also refer Amendment No. 1.
	Section VI: Schedule of Requirements	
2.	One of firms has requested to split ZLN (Zidovudine 300 mg+ Lamivudine 150 mg + Nevirapine 200 mg tablets) quantity in to 4 Schedules instead of 2 Schedules as quantity is very large. <i>(Refer Page -85)</i>	Not Agreed
3.	All the participants collectively expressed their inability to supply the 1 st Lot in 60 days and requested to amend this period to 90 days. Similarly it was also requested to take the complete supplies in 9 months instead of 6 months. <i>(Refer Page -85)</i>	The delivery schedule & Consignee-Wise Quantity Distribution has been Amended. Please refer Amendment No.1 for details. Amended Delivery Schedule is also mentioned below. (i) 25% quantity of the schedule to be supplied within 60 days, (ii) 25% quantity of the schedule to be supplied 61-120 days, (iii) 25% quantity of the schedule to be supplied 121-180 days and (iv) balance 25% within 181 to 270 days from the date of Notification of Award.
4.	Note 2. <i>(Refer Page -85):</i> “The Purchaser has the right to increase or decrease the quantities required by 25% any time during the contract period.” One of the firms has requested to reduce variation in quantity from 25% to 10%.	Not Agreed
	Section VII: Technical Specifications	
5.	<i>(Refer Page 99 to 105)</i> M/s Aurobindo Pharama has asked the following query: Refer point No.4 Primary Container: Suitable opaque plastic bottle contain 60 Tablets/ capsules. Each Bottle duly sealed with plastic plug/diaphragm and should contain silicon packs. Tightly fitting suitable screw cap. APL Specification: This product packed into HDPE Container and duly sealed with pp screw	This is as per DCGI guidelines and DAC faced some issues of broken tablets, which could be due to absence of silica gel, which probably absorbs any moisture. Therefore not agreed.

S. No.	Query Raised	Clarification
	<p>cap with no silica gel packs. They have stability data for 24 months and found well within specification limits. Hence this product does not required silica gel packs to be put in container.</p> <p>In view of above, the firm has requested to amend the clause.</p>	
	VIII. Sample Forms	
6.	<p>It was requested by participants to remove Stock Ledger details from Final Acceptance Certificate (FAC) Form as consignees take time to fill such details and some consignees issue the FAC without such details causing problem at the time of release of payment. (<i>Refer Form 17 at Page 141</i>)</p>	<p>Suitable modification in Final Acceptance Certificate (FAC) Form has been done. Please Refer Amendment No. 1 for Modified Form 17.</p>

Meeting concluded with thanks to the participants for their active participation.